Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-067 and Liso-cel in R/R Large B-Cell Lymphoma
NCT07098364Phase 2Suspended
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2025
- Primary completion
- Oct 2030
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of vevoctadekin in diffuse large B-cell lymphoma (DLBCL), sponsored by Fred Hutchinson Cancer Center. Started Dec 2025; status: suspended.
02
Drugs
vevoctadekin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07098364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07098364.